Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Parker Institute for Cancer Immunotherapy
AddedFeb 13, 2024
UpdatedJun 28, 2026
Parker Institute for Cancer Immunotherapy

Parker Institute for Cancer Immunotherapy

PICI, a San Francisco-based nonprofit, revolutionizes cancer research through innovative collaborations.

HQ
San Francisco, CA, US
Founded
2016
Overview
Compare
Employees
Website

Founded in 2016 with a $250 million donation from Silicon Valley entrepreneur Sean Parker, the Parker Institute for Cancer Immunotherapy (PICI) is a San Francisco-based nonprofit dedicated to transforming cancer research. Its core mission is to accelerate the development of breakthrough immunotherapies by fostering unprecedented collaboration among leading research institutions, scientists, and industry partners. PICI focuses on creating innovative treatments that harness the power of the immune system to combat cancer, aiming to make these therapies accessible to patients worldwide.

Notable affiliated individuals include Sean Parker, whose vision and funding were instrumental in establishing PICI. The institute collaborates with top-tier research centers such as Memorial Sloan Kettering Cancer Center and Stanford University. Key achievements include advancing numerous clinical trials and fostering significant scientific discoveries in cancer immunotherapy. PICI's collaborative model has had a profound impact on the field, driving forward new treatments and offering hope to millions affected by cancer.

Parker Institute for Cancer Immunotherapy - Quick Facts

When was Parker Institute for Cancer Immunotherapy founded?

Parker Institute for Cancer Immunotherapy was founded in 2016.

Where is Parker Institute for Cancer Immunotherapy's headquarters located?

Parker Institute for Cancer Immunotherapy's headquarters is located in San Francisco, CA, US.

How many employees does Parker Institute for Cancer Immunotherapy have?

Parker Institute for Cancer Immunotherapy has 71 employees as of Feb 4, 2024.

Classification

Technology
  • Immunotherapy
Geographic Exposure
  • United States
Customer
  • Enterprise
  • Government
  • Non-Profit
Main Product
  • Cancer Research
Tags
  • Biotech
  • Healthtech
NAICS
  • 610000Educational Services
  • 611300Colleges, Universities, and Professional Schools
  • 611310Colleges, Universities, and Professional Schools
  • 611000Educational Services
SIC
  • 8220Colleges, Universities, Professional Schools, And Junior Colleges
  • 8221Colleges, Universities, And Professional Schools
  • 8200Educational Services
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8290Schools And Educational Services, Not Elsewhere Classified
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified